Show simple item record

dc.contributor.authorSun, G.
dc.contributor.authorDavies, J.R.
dc.contributor.authorMell, T.
dc.contributor.authorHarland, M.
dc.contributor.authorSaleh, R.M.H.
dc.contributor.authorRace, Amanda D.
dc.contributor.authorLoadman, Paul
dc.contributor.authorWilliams, E.A.
dc.contributor.authorMinihane, A.M.
dc.contributor.authorHull, M.A.
dc.date.accessioned2024-08-29T08:12:53Z
dc.date.accessioned2024-08-30T11:24:11Z
dc.date.available2024-08-29T08:12:53Z
dc.date.available2024-08-30T11:24:11Z
dc.date.issued2024-02
dc.identifier.citationSun G, Davies JR, Mell T et al (2024) APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial. Prostaglandins, Leukotrienes and Essential Fatty Acids. 201: 102623.en_US
dc.identifier.urihttp://hdl.handle.net/10454/19979
dc.descriptionYesen_US
dc.description.abstractIntroduction: We examined the relationship between Apolipoprotein E (APOE) genotype and n-3 highly unsaturated fatty acid (HUFA) levels in participants of the seAFOod trial, who were undergoing colonoscopy surveillance after removal of colorectal polyps. Methods: Baseline and on-treatment (eicosapentaenoic acid [EPA] 2 g daily or placebo for 6 months) levels of n-3 HUFAs, and plasma 18-hydroxyeicosapentaenoic acid (HEPE), were analysed according to APOE genotype (based on polymorphisms rs429358 and rs7412) in 584 participants. Results: Before treatment, APOE2/2 individuals had lower levels, and APOE4/4 participants had higher levels, of n-3 HUFAs, including EPA, than APOE3/3 counterparts (P < 0.01 for the APOE2/2 versus APOE4/4 comparison). After EPA supplementation, n-3 HUFA levels were not significantly different when stratified by APOE genotype, although APOE4 carriers displayed lower plasma 18-HEPE levels than individuals without an APOE4 allele (P = 0.002). Conclusions: APOE genotype is associated with differential n-3 HUFA and 18-HEPE levels in individuals with multiple colorectal polyps.en_US
dc.description.sponsorshipThis project (NIHR128210) was funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NIHR or the Department of Health and Social Care. MAH is a NIHR Senior Investigator. MAH is supported by Cancer Research UK grant C23434/A24939.en_US
dc.languageen
dc.language.isoenen_US
dc.rights© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectApolipoprotein Een_US
dc.subjectColorectal polypen_US
dc.subjectHighly unsaturated fatty aciden_US
dc.subjectOxylipinen_US
dc.subjectSingle nucleotide polymorphismen_US
dc.titleAPOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trialen_US
dc.status.refereedYesen_US
dc.date.application2024-05-31
dc.typeArticleen_US
dc.type.versionPublished versionen_US
dc.identifier.doihttps://doi.org/10.1016/j.plefa.2024.102623en_US
dc.rights.licenseCC-BYen_US
dc.date.updated2024-08-29T08:12:55Z
refterms.dateFOA2024-08-30T11:25:24Z
dc.openaccess.statusopenAccessen_US
dc.date.accepted2024-05-22


Item file(s)

Thumbnail
Name:
APOEgenotype.pdf
Size:
1.759Mb
Format:
PDF
Description:
Loadman_et_al_PLEFA
Thumbnail
Name:
APOEgenotype.pdf
Size:
1.759Mb
Format:
PDF
Description:
To keep suppressed

This item appears in the following Collection(s)

Show simple item record